PubMed HealthSearch

PubMed · 435406

The adrenalin binding site on human platelets.

Abstract

Using 3H-adrenalin the quantity and characteristics of the adrenalin receptors on human platelets were evaluated. Maximum adrenalin binding by intact platelets from eight normal subjects averaged 3.2 ng adrenalin/10(8) platelets, equivalent to 105 000 binding sites per platelet. Bound 3H-adrenalin could be dissociated or binding could be inhibited by an excess of unlabelled adrenalin, noradrenalin, isoproterenol or dopamine; phentolamine or propanalol had no effect on 3h-adrenalin binding, even in concentrations 10 000-fold greater. These studies show that the epinephrine binding site can be detected and quantitiated on human platelets and that its characteristics differ from those classically attributed to either alpha or beta adrenergic receptors.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

R McMillan, M J Bakich, R J Yelenosky. 1979. The adrenalin binding site on human platelets.. https://doi.org/10.1111/j.1365-2141.1979.tb05896.x

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Stereoselectivity of a radioimmunoassay for the insecticide S-bioallethrin.

The stereoselectivity of a radioimmunoassay (RIA) system using an S-bioallethrin specific antiserum was studied by observing the abilities of the 8 allethrin isomers and other selected compounds to compete with a radiolabelled S-bioallethrin tyramine derivative for antibody binding sites. The results demonstrate the feasibility of RIA as a rapid, sensitive and steroselective residue technique for compounds difficult to analyze by classical methods.

Binding, Competitive

A comparative study on estradiol receptor assays in human breast cancer tissue.

Standard dextran-coated charcoal assays for measuring the estrogen receptor content in human breast cancer tissue are compared. A single-point assay, using the estrogen antagonist nafoxidine as competitive inhibitor, showed good qualitative agreement with a three-point Scatchard plot assay, using radio-inert estrogen to assess the non-specific binding. Based on statistically evaluated dividing points, 116 (66.3%) of the 175 analysed primary tumor specimens were positive in the single-point assay compared to 121 (69.1%) in the Scatchard plot assay. Use of the additional dissociation constants in the evaluation of the Scatchard plot assay data gives a complete qualitative agreement between the two assays. We conclude that, in spite of the lack of specific controls inherent in the Scatchard plot assay, the single-point assay using diethylstilbestrol instead of nafoxidine is equally useful, especially if biopsy specimens are too small to provide the larger number of aliquots necessary for multiple steroid receptor analyses. Factors affecting the quantitative differences between the two assays are discussed.

Binding, Competitive